The FDA has issued a Proposal to Withdraw Marketing Approval for Primetime (midodrine HCl), which is used in the treatment of orthostatic hypotension, The agency claimed required post-approval studies that verify the clinical benefit of the drug have not been done.
http://www.fda.gov/